• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

FDA Slows Down Accelerated Approval Pathway Products Program


With drugs taking longer to hit the market, will biopharma’s approval count be affected?

Silver Spring, MD, USA 11/10/2020: Exterior view of the headquarters of US Food and Drug Administration (FDA). This federal agency approves medications, vaccines and food additives for human use. Image Credit: Adobe Stock Images/Grandbrothers

Image Credit: Adobe Stock Images/Grandbrothers

According to data taken by Evaluate Vantage, only 12 percent of novel drugs arrived on the market last year via the FDA’s accelerated approval pathway program. As a result of a new restriction, a further decline of approved medicines can be expected by the end of 2023.

Heavy use of this feature in recent years provided a massive boost to the FDA’s approval count, peaking at 58 percent in 2021. Speedy approval in niche and underserved settings can of course benefit patients in the longer term, but the need to establish both the risks and benefits of these agents, as expeditiously as possible, remains.


The Waxing and Waning of the Speedy Approval. May 15, 2023 / Evaluate

Related Videos